Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study.

Publication
Title	Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Authors	Francisco Membrillo German Ramirez-Olivencia Miriam Estebanez ... Lucia Ballester
Journal	Preprints.org
Date	May 6, 2020

Observational study in Spain of early treatment with hydroxychloroquine in 166 COVID-19 patients showed a significant survival benefit in patients started on hydroxychloroquine in the mild stage of disease.

Patients were categorized into one of three groups at initial presentation: mild, moderate or severe. There was a significant survival benefit in the mild group compared to controls (1.8 times, p = 0.032) and a trend toward survival benefit in the moderate and severe groups (1.4 times and 1.6 times, respectively). Of note, the average time between symptom onset and treatment was 7 days.

Major Issues

No major issues identified.

Minor Issues

No minor issues identified.

Impact

This is another retrospective analysis that suggests efficacy of early treatment with hydroxychloroquine against COVID-19.

Article Revisions

None at this time.